Velocity Clinical Research Germany GmbH — Clinical Trial Site

61 Registered trials

50 Currently recruiting

Organisation

Velocity Clinical Research Germany GmbH

Location

Ahrensburg, Germany

Identifier

ORG-100042412

Address

Wöhrendamm 80, 22927, Germany

Departments

--
#2102
#2601
#2602
#3000: Velocity Clinical Research Germany GmbH
2602: Pneumology
2603
2603: Pulmonology
2605
276007: Pneumology
3440
4510: Internal medicine
4513: Internal medicine
KLB Gesundheitsforschung Lubeck GmbH( #1)
KLB Gesundheitsforschung Luebeck GmbH
Klinische Forschung Berlin GbR
Location Ahrensburg
Location Luebeck
LungenClinic Grosshansdorf GmbH
N/A
NA
Physician
Pneumologisches Forschungsinstitut
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
Pneumologisches Forschungsinstitut( #1)
Practice
Pulmonary research
Pulmonology
Pulmunology
Research
Standort Berlin
Standort Grosshansdorf
Standort Grosshansdorf, Pneumologisches Forschungsinstitut
Standort Leipzig
Standort Lübeck
Velocity Clinical Reasearch - Ahrensburg
Velocity Clinical Research Germany GmbH
Velocity Clinical Research Germany GmbH
Velocity Clinical Research Germany GmbH - Berlin
Velocity Clinical Research Germany GmbH - Hamburg
Velocity Clinical Research Germany GmbH - Leipzig
Velocity Clinical Research Germany GmbH - Wiesbaden
Velocity Clinical Research Germany GmbH, Location Leipzig
Velocity Clinical Research Lübeck

Clinical trials at this site (61)

Search interface

A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat… Pending

2022-502365-26-00 Asthma 5
A Study to Learn About the Study Medicine Called PF-07275315 in Adults with Moderate-To-Severe Long-Term Breathing Difficulty, Known by the… Pending

2024-518587-12-00 MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEAS 4
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending

2024-518821-13-00 Non-cystic Fibrosis Bronchiectasis 4
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Recruiting

2025-521950-41-00 severe uncontrolled asthma 5 2026-06-05
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm… Recruiting

2025-521268-37-00 Respiratory tract diseases 6 2025-11-25
The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting

2024-518589-29-00 Bronchiectasis 5 2025-08-21
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Progressive Pulmonary Fibrosis 5 2024-07-15
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Idiopathic pulmonary fibrosis 5 2024-06-24
Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting

2023-503290-38-00 Bronchiectasis 4 2023-09-05
eValuating the efficacy and safety of InitiatinG depemokImab earLy therApy iN COPD with Type 2 inflammation (VIGILANT) Recruiting

2025-521108-23-00 Chronic Obstructive Pulmonary Disease 5 2026-05-19
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-0… Recruiting

2025-524987-39-00 Mild to Moderate Asthma 3 2026-05-04
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting

2024-516411-24-00 Insomnia Disorder 5 2026-02-25
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A study to investigate the efficacy, safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation Recruiting

2025-520518-79-00 Atrial Fibrillation 4 2026-01-06
A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 … Recruiting

2025-521391-58-00 Asthma 4 2025-11-28
Silexan® in mild to moderate major depressive disorder Recruiting

2025-521744-37-00 Mild to moderate major depressive disorder 5 2025-11-17
A study to investigate the effect of BGF MDI compared with placebo MDI on heart and lung function in participants with COPD Recruiting

2025-521987-37-00 Chronic Obstructive Pulmonary Disease 6 2025-11-06
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting

2025-520473-40-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 4 2025-09-29
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03